Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 8, 1999, Pages 2007-2011

  Geiger, J ^a   Brich, J ^a   Honig Liedl P ^a   Eigenthaler, M ^a   Schanzenbacher P ^a   Herbert, J M ^b   Walter, U ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b SANOFI   (France)

Author keywords

Platelet inhibition; Purinergic receptors; Vasodilator stimulated phosphoprotein

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; CLOPIDOGREL; PHOSPHOPROTEIN; PROSTAGLANDIN E1; PURINE P2Y RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 0032800250     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.8.2007     Document Type: Article

References (37)

1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
2. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med. 1994;330:956-961.
5. Schrör K. Antiplatelet drugs: a comparative review. Drugs. 1995; 50:7-28.
6. Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med. 1998;338:1539-1540.
7. Gaardner A, Jonsen J, Laland S, Hellem A, Owen PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 1961;192:531-532.
8. Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial point of view. Circulation. 1985;72:741-742.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
10. Savi P, Heilmann E, Nurden P, Laplace M-C, Bihour C, Kieffer G, Nurden AT, Herbert J-M. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 1996;2:35-42.
11. Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79-82.
12. Gachet C, Hechler B, Léon C, Vial C, Leray C, Ohlmann P, Cazenave J-P. Activation of ADP receptors and platelet function. Thromb Haemost. 1997;78:271-275.
13. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I. J Biol Chem. 1998;273:2024-2029.
14. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation, II. J Biol Chem. 1998;273:2030-2034.
15. Geiger J, Hönig-Liedl P, Schanzenbächer P, Walter U. Ligand specificity and ticlopidine effects distinguish three platelet ADP receptors. Eur J Pharmacol. 1998;351:235-246.
16. Savi P, Beuvarger P, Labouret C, Deflaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998;422:291-295.
17. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95:8070-8074.
18. Hechler B, Leo C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood. 1998;92:152-159.
19. Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol. 1998;124:157-164.
20. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J. 1998;336:513-523.
21. Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of adenylate cyclase of human platelets by PGE1. Biochem Pharmacol. 1990;40:2683-2687.
22. Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186-190.
23. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430-436.
24. Hardisty EM, Powling MJ, Nokes TJ. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost. 1990;64:150-155.
25. Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532-1543.
26. Smolenski A, Bachmann C, Reinhard K, Hönig-Liedl P, Jarchau T, Hoschuetzky H, Walter U. Analysis and regulation of VASP serine 239 phosphorylation in vitro and in intact cells using a phosphospecific antibody. J Biol Chem. 1998;273:20029-20035.
27. Reinhard M, Halbrügge M, Scheer U, Wiegand C, Jockusch BM, Walter U. The 46/50 kDa phosphoprotein VASP purified from human platelets in a novel actin filament- and focal contact-associated protein. EMBO J. 1992;11:2063-2070.
28. Reinhard M, Jarchau T, Walter U. VASP. In: Kreis T, Vale R, eds. Guidebook to the Cytoskeletal and Motor Proteins. Oxford, England: Oxford University Press; In press.
29. Shattil SJ, Kashiwagi H, Pampori M. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645-2657.
30. Horstrup K, Jablonka B, Hönig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of the focal adhesion protein VASP at serine 157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994;225:21-27.
31. 3H]-2-methylthio-ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994;269:772-777.
32. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and calcium entry in human platelets by cyclic nucleotide-elevating and endothelium-derived factors. Am J Physiol. 1994;267:C236-C244.
33. Nolte C, Eigenthaler M, Schanzenbächer P, Walter U. Endothelial cell-dependent phosphorylation of a platelet protein mediated by cAMP- and cGMP-elevating factors. J Biol Chem. 1991;266:14808-14812.
34. Pohl U, Nolte C, Bunse A, Eigenthaler M, Walter U. Endothelium-dependent phosphorylation of the platelet protein VASP during a single passage of human platelets through the rabbit coronary bed. Am J Physiol. 1994;266:H606-H612.
35. Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson K-E, Kehrel B, Offermanns S, Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP-and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999;18:37-48.
36. Hauser W, Knobeloch K-P, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, Glazova M, Rohde E, Horak I, Walter U, Zimmer M. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein (VASP)-knock-out mice. Proc Natl Acad Sci U S A. In press.
37. Clapham DE, Neer EJ. G protein βγ subunits. Annu Rev Pharmacol Toxicol. 1997;37:167-203.